Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2026 08:00 ET | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and...
March 10, 2026 08:59 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market...
March 10, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
February 25, 2026 21:22 ET | Source: MindRank AI Ltd.

MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001

MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.
February 25, 2026 08:05 ET | Source: Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals Announces Appointment of Pharmaceutical Veteran Jorge Bartolome as CEO
February 25, 2026 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Novo Nordisk and Vivtex Corp announced partnership to develop next-generation oral biologic medicines for obesity, diabetes + associated comorbidities
February 24, 2026 07:35 ET | Source: Jeito Capital

Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million

Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program ALV‑100 designed to deliver potent, durable weight loss and long‑term maintenance with improved...
February 24, 2026 07:30 ET | Source: Alveus Therapeutics Inc

Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases

Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega FundsAdditional capital further supports clinical...
February 19, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
February 12, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Leadership Appointments

Aardvark Therapeutics Announces Leadership Appointments